Stefanello Josias R, Piasentin Fernanda B, Tondolo Juliana S M, Loreto Erico S, Dutra Valéria, Alves Sydney H, Santurio Janio M
Programa de Pós-Graduação em Farmacologia, Centro de Ciências da Saúde, Departamento de Microbiologia e Parasitologia, Universidade Federal de Santa Maria (UFSM), RS, Brazil.
Programa de Pós-Graduação em Ciências Veterinárias, Universidade Federal do Mato Grosso, Cuiabá, MG, Brazil.
Med Mycol. 2019 Jul 1;57(5):649-652. doi: 10.1093/mmy/myy092.
We have determined the in vitro activity of antifungal, antibacterial, and antiprotozoal drugs alone and in combination against seven Conidiobolus lamprauges clinical isolates. The assays were based on the M38-A2 protocol and the checkerboard microdilution method. The lowest inhibitory concentrations were observed for amphotericin B, miconazole (MCZ), terbinafine, and miltefosine (MTF) (MIC range 0.25-1; 2-8; 0.25-2; 2-16 μg/ml, respectively). The main synergism observed was through the combination of azithromycin (AZI)+MTF and dapsone (DAP)+MTF (100%), AZI+DAP (85.7%), AZI+MCZ (57.1%) as well as MCZ plus CTX and DAP (42.9%). The in vitro activities suggest that the combination of MTF and AZI or DAP are promising candidate therapies for conidiobolomycosis.
我们已经测定了抗真菌、抗菌和抗原虫药物单独及联合使用对七株鲁氏耳霉临床分离株的体外活性。试验基于M38 - A2方案和棋盘微量稀释法。两性霉素B、咪康唑（MCZ）、特比萘芬和米替福新（MTF）的最低抑菌浓度最低（MIC范围分别为0.25 - 1；2 - 8；0.25 - 2；2 - 16μg/ml）。观察到的主要协同作用是通过阿奇霉素（AZI）+MTF和氨苯砜（DAP）+MTF（100%）、AZI+DAP（85.7%）、AZI+MCZ（57.1%）以及MCZ加CTX和DAP（42.9%）的组合。体外活性表明，MTF与AZI或DAP的组合是治疗耳霉病的有前景的候选疗法。
